News und Analysen

No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.

Three Motley Fool contributors think they've

Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still

If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.

That answer will be terrible

Medtronic (NYSE: MDT) is a leading global medical device company with a massive presence that spans more than 150 countries. Its products assist patients with over 70 different health conditions

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical

For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side).

Some good news from a clinical trial conducted by Eli Lilly

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q1 2024 Earnings CallApr 17, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q1 2024 Earnings CallApr 16, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of UnitedHealth Group (NYSE: UNH) were jumping 5.7% higher as of 11:17 a.m. ET on Tuesday after rising as much as 7.7% earlier in the day. The solid gain came after the giant healthcare

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to

Big pharma stocks like AbbVie (NYSE: ABBV) usually aren't high on the list that investors look to for opportunities that could make them into millionaires. After all, they aren't typically in the

The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered

Investing for the long term, as opposed to day trading, offers many benefits. Holding shares of companies for a while arguably brings more peace of mind, some tax advantages, and the ability for

Income-seeking investors have to make an important choice when shopping for stocks to buy. Shares of companies that are likely to raise their dividend payouts at a rapid pace tend to offer low

Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare

Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now

Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to

There are plenty of things to buy with $200. But what about investing in a company that can grow your capital for years? Though some people believe they need millions, or at least thousands, to

Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in

One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.